| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Poseida Therapeutics, Inc. | President, Gene Therapy | Common Stock | 419,040 | $1,730,635 | $4.13 | 01 Mar 2024 | Direct |
| Poseida Therapeutics, Inc. | President, Gene Therapy | Employee Stock Option (Right to Buy) | 111,700 | 01 Mar 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| /report/000095017024024920-warner-brent-2024-03-01 | Poseida Therapeutics, Inc. | 01 Mar 2024 | 3 | -$147,602 | 4 | President, Gene Therapy | 04 Mar 2024, 17:18 |
| /report/000120919123014910-warner-brent-2023-03-01 | Poseida Therapeutics, Inc. | 01 Mar 2023 | 3 | -$142,401 | 4 | President, Gene Therapy | 02 Mar 2023, 17:30 |
| /report/000120919122014372-warner-brent-2022-03-01 | Poseida Therapeutics, Inc. | 01 Mar 2022 | 2 | $0 | 4 | President, Gene Therapy | 01 Mar 2022, 18:27 |
| /report/000120919122014371-warner-brent-2022-02-21 | Poseida Therapeutics, Inc. | 21 Feb 2022 | 0 | $0 | 3 | President, Gene Therapy | 01 Mar 2022, 18:26 |